Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC
Nature Reviews Clinical Oncology - Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC
Nature Reviews Clinical Oncology - Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC